Author(s): Pumariega AJ, Nelson R, Rotenberg L
Abstract Share this page
Abstract Varenicline is a promising agent with demonstrated efficacy in the promotion of smoking cessation. However, from the time of initial trials, it has been associated with significant psychiatric adverse effects. We describe a case where mixed mood and psychotic disturbance developed in an individual with a history of depression and a family history of bipolar disorder. Based on this case, we hypothesize a possible mechanism of action for these adverse effects and preventive measures that could be undertaken in its effective use.
This article was published in CNS Spectr
and referenced in Journal of Addiction Research & Therapy